136 related articles for article (PubMed ID: 11118849)
21. In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus.
Firsov AA; Vostrov SN; Lubenko IY; Drlica K; Portnoy YA; Zinner SH
Antimicrob Agents Chemother; 2003 May; 47(5):1604-13. PubMed ID: 12709329
[TBL] [Abstract][Full Text] [Related]
22. Pharmacodynamics of gemifloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model of infection.
MacGowan AP; Rogers CA; Holt HA; Wootton M; Bowker KE
Antimicrob Agents Chemother; 2001 Oct; 45(10):2916-21. PubMed ID: 11557490
[TBL] [Abstract][Full Text] [Related]
23. In vitro activity of gatifloxacin compared with gemifloxacin, moxifloxacin, trovafloxacin, ciprofloxacin and ofloxacin against uropathogens cultured from patients with complicated urinary tract infections.
Naber KG; Hollauer K; Kirchbauer D; Witte W
Int J Antimicrob Agents; 2000 Nov; 16(3):239-43. PubMed ID: 11091042
[TBL] [Abstract][Full Text] [Related]
24. Cellular accumulation of fluoroquinolones is not predictive of their intracellular activity: studies with gemifloxacin, moxifloxacin and ciprofloxacin in a pharmacokinetic/pharmacodynamic model of uninfected and infected macrophages.
Vallet CM; Marquez B; Ngabirano E; Lemaire S; Mingeot-Leclercq MP; Tulkens PM; Van Bambeke F
Int J Antimicrob Agents; 2011 Sep; 38(3):249-56. PubMed ID: 21764262
[TBL] [Abstract][Full Text] [Related]
25. Parameters of bacterial killing and regrowth kinetics and antimicrobial effect examined in terms of area under the concentration-time curve relationships: action of ciprofloxacin against Escherichia coli in an in vitro dynamic model.
Firsov AA; Vostrov SN; Shevchenko AA; Cornaglia G
Antimicrob Agents Chemother; 1997 Jun; 41(6):1281-7. PubMed ID: 9174184
[TBL] [Abstract][Full Text] [Related]
26. Twenty-four-hour area under the concentration-time curve/MIC ratio as a generic predictor of fluoroquinolone antimicrobial effect by using three strains of Pseudomonas aeruginosa and an in vitro pharmacodynamic model.
Madaras-Kelly KJ; Ostergaard BE; Hovde LB; Rotschafer JC
Antimicrob Agents Chemother; 1996 Mar; 40(3):627-32. PubMed ID: 8851583
[TBL] [Abstract][Full Text] [Related]
27. [Investigation of the effect of efflux pump inhibitors to MIC values of ciprofloxacin in clinical isolates of Pseudomonas aeruginosa, Escherichia coli, Acinetobacter baumannii and Staphylococcus aureus].
Cetinkaya E; Coban AY; Durupinar B
Mikrobiyol Bul; 2008 Oct; 42(4):553-61. PubMed ID: 19149076
[TBL] [Abstract][Full Text] [Related]
28. In vitro activity of gemifloxacin against a broad range of recent clinical isolates from the USA.
McCloskey L; Moore T; Niconovich N; Donald B; Broskey J; Jakielaszek C; Rittenhouse S; Coleman K
J Antimicrob Chemother; 2000 Apr; 45 Suppl 1():13-21. PubMed ID: 10824027
[TBL] [Abstract][Full Text] [Related]
29. Simulated in vitro quinolone pharmacodynamics at clinically achievable AUC/MIC ratios: advantage of I E over other integral parameters.
Firsov AA; Zinner SH; Lubenko IY; Portnoy YA; Vostrov SN
Chemotherapy; 2002; 48(6):275-9. PubMed ID: 12673102
[TBL] [Abstract][Full Text] [Related]
30. Comparison of in-vitro pharmacodynamics of once and twice daily ciprofloxacin.
Bowker KE; Wootton M; Rogers CA; Lewis R; Holt HA; MacGowan AP
J Antimicrob Chemother; 1999 Nov; 44(5):661-7. PubMed ID: 10552983
[TBL] [Abstract][Full Text] [Related]
31. ABT492 and levofloxacin: comparison of their pharmacodynamics and their abilities to prevent the selection of resistant Staphylococcus aureus in an in vitro dynamic model.
Firsov AA; Vostrov SN; Lubenko IY; Arzamastsev AP; Portnoy YA; Zinner SH
J Antimicrob Chemother; 2004 Jul; 54(1):178-86. PubMed ID: 15190041
[TBL] [Abstract][Full Text] [Related]
32. Gemifloxacin: effects of sub-inhibitory concentrations on various factors affecting bacterial virulence.
Dal Sasso M; Culici M; Bovio C; Braga PC
Int J Antimicrob Agents; 2003 Apr; 21(4):325-33. PubMed ID: 12672578
[TBL] [Abstract][Full Text] [Related]
33. Antibacterial properties of gemifloxacin and trovafloxacin in urine ex vivo: phase I study.
García-Calvo G; Parra A; Aguilar L; Ponte C; Giménez MJ; Carcas A; Kinzig-Schippers M; Soriano F
Antimicrob Agents Chemother; 2001 Jun; 45(6):1876-8. PubMed ID: 11353641
[TBL] [Abstract][Full Text] [Related]
34. The bactericidal activity of gemifloxacin (SB-265805).
Morrissey I; Clark S; Mathias I
J Med Microbiol; 2000 Sep; 49(9):841-844. PubMed ID: 10966234
[TBL] [Abstract][Full Text] [Related]
35. Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli: simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model.
Odenholt I; Cars O
J Antimicrob Chemother; 2006 Nov; 58(5):960-5. PubMed ID: 16936293
[TBL] [Abstract][Full Text] [Related]
36. Comparative in vitro activity of gemifloxacin, ciprofloxacin, levofloxacin and ofloxacin in a North American surveillance study.
Hoban DJ; Bouchillon SK; Johnson JL; Zhanel GG; Butler DL; Miller LA; Poupard JA;
Diagn Microbiol Infect Dis; 2001; 40(1-2):51-7. PubMed ID: 11448564
[TBL] [Abstract][Full Text] [Related]
37. Differences between two new quinolones (gemifloxacin and trovafloxacin) and ciprofloxacin in their concentration-dependent killing of Streptococcus pneumoniae.
Joyanes P; Pascual A; Giménez MJ; García I; Aguilar L; Perea E
Chemotherapy; 2001 Dec; 47(6):409-14. PubMed ID: 11786655
[TBL] [Abstract][Full Text] [Related]
38. In vitro susceptibility to gemifloxacin and trovafloxacin of Streptococcus pneumoniae strains exhibiting decreased susceptibility to ciprofloxacin.
Fuentes F; Giménez MJ; Marco F; Alou L; Aguilar L; Prieto J
Eur J Clin Microbiol Infect Dis; 2000 Feb; 19(2):137-9. PubMed ID: 10746503
[TBL] [Abstract][Full Text] [Related]
39. Pharmacodynamics to combat resistance.
Woodnutt G
J Antimicrob Chemother; 2000 Jul; 46 Suppl T1():25-31. PubMed ID: 10997596
[TBL] [Abstract][Full Text] [Related]
40. [The pharmacodynamics and pharmacokinetics of fluoroquinolones in the evaluation of antibacterial therapy regimens].
Smirnova LB; Sokolova VI
Antibiot Khimioter; 2000; 45(7):14-6. PubMed ID: 10987102
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]